Truist analyst Jailendra Singh raised the firm’s price target on Icon to $367 from $357 and keeps a Buy rating on the shares after its Q4 results. The company hs seen a more solid trajectory with actual business wins so far this year, though the management also noted that during 2023, large pharmas re-engineered their models and outsourcing, which affected timing of business awards, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICLR: